Janux Therapeutics saw a significant increase in stock value as its prostate cancer treatment, JANX007, showed promising results in a Phase 1a trial. The drug will now undergo expansion trials for patients who haven't used existing therapies, potentially addressing an unmet medical need.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing